Thursday, September 08, 2022
Medable Inc., a leading provider of software for patient-centered clinical trials, has announced a four-year enterprise contract with GSK (GlaxoSmithKline) to facilitate decentralized clinical trials (DCTs) across GSK's portfolio using Medable's advanced DCT platform. GSK selected Medable to expedite the development of new medications and ensure that their clinical trials are more inclusive and representative of diverse patient populations.
After conducting a thorough evaluation of various clinical trial platforms, GSK chose Medable's technology because it aligns best with GSK's objectives of enhancing research access, improving diversity, and creating patient-centric trial designs. Medable's comprehensive DCT platform offers essential digital capabilities such as eConsent, TeleVisit, and eCOA (electronic Clinical Outcome Assessments), while also providing the flexibility to implement modern, patient-centered clinical trials.
Dr. Michelle Longmire, Co-founder and CEO of Medable, expressed gratitude at being chosen as GSK's preferred partner for decentralized clinical trials. She commended GSK for its longstanding commitment to innovative science and highlighted the transformative nature of leveraging a modern, patient-centric model for conducting clinical trials in collaboration with Medable. Dr. Longmire eagerly anticipates the opportunity to make a significant impact on the lives of millions of patients through this partnership.
Medable's software-as-a-service platform has already been deployed in over 300 decentralized and hybrid clinical trials across 60 countries, benefiting over one million patients and research participants globally. Medable's customers have achieved remarkable results with decentralized and hybrid trials, including 200% faster enrollment and 50% cost reductions. A recent financial modeling study conducted by the Tufts Center for the Study of Drug Development in 2022, which considered industry benchmarks and data from Medable, demonstrated that decentralized trials can yield net financial benefits ranging from five to 13 times for Phase II and Phase III trials. These benefits arise from reduced trial timelines and other contributing factors.
To learn more about Medable's partnership with GSK and its collaborations with other leaders in the life science industry, interested parties can visit booth #48 at the 12th annual DPharm Disruptive Innovations U.S. conference in Boston, scheduled for September 13-14, 2022
